跳至主要内容
临床试验/NCT02191332
NCT02191332已完成不适用

Collecting Data in Patients With HIV Infection Type 1 After Switching From a Protease Inhibitor-containing Therapy Regimen and a Viral Load Below Detection Level to a Viramune®-Containing Therapy Regimen

Boehringer Ingelheim0 个研究点目标入组 147 人开始时间: 1999年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
147
主要终点
Change in viral load (HIV-RNA)

研究概览

简要总结

Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult male or female patients with HIV type 1 infection

排除标准

  • Counter-indications according to summary of product characteristics (SPC) for Viramune tablets
  • No persons under 18
  • Pregnancy and breast-feeding
  • Use of oral contraceptives
  • Use of drugs affecting CYP450 3A metabolism

研究组 & 干预措施

Viramune

干预措施: Viramune (Drug)

结局指标

主要结局

Change in viral load (HIV-RNA)

时间窗: Baseline, after 26 and 52 weeks

Change in CD4 cell count

时间窗: Baseline, after 26 and 52 weeks

Change in glucose tolerance

时间窗: Baseline, after 26 and 52 weeks

verbal rating scale

Change in lipid status (lipodystrophy, triglycerides, cholesterol)

时间窗: Baseline, after 26 and 52 weeks

verbal rating scale

次要结局

  • Assessment of tolerability by physician and patient(after 26 and 52 weeks)
  • Number of patients with adverse events(up to 52 weeks)
  • Assessment of subjective well-being(up to 52 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Observational Study in Patients With HIV Infection... | 临床试验